Introduction
The discovery in 1969
1 that cisplatin has antitumor activity has led to the use of this compound in the chemotherapy of several types of human tumors (for a review see ref. 2) . Although the site of action of cisplatin is not certain it is thought that DNA is the critical target. 3 The human immunodeficiency virus (HIV) is the causative agent of the acquired immune deficiency syndrome (AIDS) (for a review see ref. 4) . AIDS patients are at increased risk from a variety of cancers, including Kaposi's sarcoma, non-Hodgkin's lymphoma, squamous cell carcinoma, testicu lar cancers, malignant melanoma, primary hepato cellular carcinoma and Hodgkin's disease. 4 The HIV-1 LTR contains a variety of regulatory sequences (for a review see ref.
5). We have
Corresponding Author previously shown that cisplatin transcriptionally activates the HIV LTR sequences in rat fibroblasts. 6 In the present study we have examined the effect of cisplatin on the HIV LTR in human fibroblasts and found that cisplatin also stimulates transcriptional activation significantly in this system.
Materials and methods

Recombinant plasmids and cell lines
Plasmid pBHIVl was derived from plasmid pBC12/HIV/CAT 7 by inserting a 1.9 kb BamHl fragment carrying the aph gene into the single BamHl site. Plasmid pBC12/HIV/CAT carries a 728 bp Xhol-Hindlll DNA fragment containing the HIV LTR sequences linked to the CAT reporter gene.
The MRCSV40TGR human fibroblasts were obtained after immortalization of MRC cells with SV40 and are resistant to 6-thioguanine. SVTGHIV1-1 cells were obtained after transfection with plasmid pBHIVl and selection in the presence of geneticin.
CAT assays
Cells were grown exponentially in Ham's medium containing 10% fetal calf serum and assayed for CAT activity as previously described. 8 
Assay for cell proliferation
The rapid colorimetrie assay for cell proliferation of Mossmann 9 was used as previously described.
V Zoumpourlis et al. The recipient MRCSV40TGR and the transfectant SVTGHIV1-1 cells were treated with cisplatin at various concentrations. A representative CAT assay is shown in Figure 1 (a) and the corresponding histogram in Figure 1(b) . Optimal stimulation was obtained at 5 x 10" 5 M, where CAT activity increased 2.2-fold. As shown in Figure 2 a time course revealed that 24 h exposure to cisplatin gave rise to maximal activation. 
Results
Effect of other anti-neoplastic compounds on HIV LTR activation
Two other compounds with known antineoplastic properties-D17872, a benzylethylenediamine de rivative of cisplatin, 10 and D18506, a hexadecylphosphocholine compound 11 -were employed at concentrations similar to that of cisplatin (5 X 10 -5 M) to test their effect on HIV LTR activation. As shown in Figure 3 , only the D17872 compound activated the HIV LTR at 1.7-fold, much below the activation caused by cisplatin. 
Cisplatin toxicity
The effect of cisplatin on SVTGHIV1-1 cells was measured by a rapid cell proliferation assay. SVTGHIV1-1 cells were exposed for various times (0, 24, 48, 72, 96, 120 h) at a range of concentrations of the drug (from 5 x 10" 7 M to 1 χ IO -4 M (Figure 4) .
The same initial number of cells was used for each concentration. Toxicity was measured, using Mosmann's colorimetrie MTT assay. As seen in Figure 4 , at the concentration where the cisplatin was most effective in stimulating the HIV LTR (5 X 10~5M) it was strongly inhibitory for cell proliferation.
Discussion
The human immunodeficiency virus LTR contains several defined regulatory domains. 5 These can be «j·- 12 ' 13 or trans-acting sequences responding to cellular 14 or viral 13 gene products. In a previous study we have found that cisplatin at 5 x ΙΟ -3 M concentrations stimulated by 22-fold the expression of the reporter CAT gene from the HIV LTR in rat fibroblasts. 6 In the present study we have found that in human fibroblasts cisplatin enhances the HIV LTR although at a much lower level (2.2-fold) (Figure 1) . Again, it is of interest that the effect of cisplatin is observed when cell proliferation is strongly suppressed (Figure 4) . Since cisplatin potentiates the activity of HIV LTR as shown before in rat, 6 and as shown here in human, fibroblasts we urged further caution when considering therapy including this compound in the treatment of AIDS patients carrying tumors.
